Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.
Identifieur interne : 001167 ( Main/Corpus ); précédent : 001166; suivant : 001168Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.
Auteurs : Simin Dashti-Khavidaki ; Hossein Khalili ; Anahid NourianSource :
- Iranian journal of kidney diseases [ 1735-8604 ] ; 2020.
English descriptors
- KwdEn :
- Betacoronavirus (isolation & purification), COVID-19 (MeSH), Comorbidity (MeSH), Coronavirus Infections (classification), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug-Related Side Effects and Adverse Reactions (classification), Drug-Related Side Effects and Adverse Reactions (etiology), Drug-Related Side Effects and Adverse Reactions (prevention & control), Humans (MeSH), Pandemics (MeSH), Patient Selection (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Renal Insufficiency, Chronic (drug therapy), Renal Insufficiency, Chronic (epidemiology), Risk Assessment (MeSH), SARS-CoV-2 (MeSH).
- MESH :
- classification : Coronavirus Infections, Drug-Related Side Effects and Adverse Reactions.
- complications : Coronavirus Infections.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Renal Insufficiency, Chronic.
- epidemiology : Coronavirus Infections, Pneumonia, Viral, Renal Insufficiency, Chronic.
- etiology : Drug-Related Side Effects and Adverse Reactions.
- isolation & purification : Betacoronavirus.
- prevention & control : Drug-Related Side Effects and Adverse Reactions.
- COVID-19, Comorbidity, Humans, Pandemics, Patient Selection, Risk Assessment, SARS-CoV-2.
Abstract
Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19.
PubMed: 32655019
Links to Exploration step
pubmed:32655019Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.</title><author><name sortKey="Dashti Khavidaki, Simin" sort="Dashti Khavidaki, Simin" uniqKey="Dashti Khavidaki S" first="Simin" last="Dashti-Khavidaki">Simin Dashti-Khavidaki</name><affiliation><nlm:affiliation>Nephrology Rsearch Center, Tehran University of Medical Sciences, Tehran, Iran. dashtis@sina.tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Khalili, Hossein" sort="Khalili, Hossein" uniqKey="Khalili H" first="Hossein" last="Khalili">Hossein Khalili</name></author><author><name sortKey="Nourian, Anahid" sort="Nourian, Anahid" uniqKey="Nourian A" first="Anahid" last="Nourian">Anahid Nourian</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32655019</idno><idno type="pmid">32655019</idno><idno type="wicri:Area/Main/Corpus">001167</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001167</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.</title><author><name sortKey="Dashti Khavidaki, Simin" sort="Dashti Khavidaki, Simin" uniqKey="Dashti Khavidaki S" first="Simin" last="Dashti-Khavidaki">Simin Dashti-Khavidaki</name><affiliation><nlm:affiliation>Nephrology Rsearch Center, Tehran University of Medical Sciences, Tehran, Iran. dashtis@sina.tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Khalili, Hossein" sort="Khalili, Hossein" uniqKey="Khalili H" first="Hossein" last="Khalili">Hossein Khalili</name></author><author><name sortKey="Nourian, Anahid" sort="Nourian, Anahid" uniqKey="Nourian A" first="Anahid" last="Nourian">Anahid Nourian</name></author></analytic><series><title level="j">Iranian journal of kidney diseases</title><idno type="eISSN">1735-8604</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (classification)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (classification)</term><term>Drug-Related Side Effects and Adverse Reactions (etiology)</term><term>Drug-Related Side Effects and Adverse Reactions (prevention & control)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Patient Selection (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Renal Insufficiency, Chronic (drug therapy)</term><term>Renal Insufficiency, Chronic (epidemiology)</term><term>Risk Assessment (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Coronavirus Infections</term><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Comorbidity</term><term>Humans</term><term>Pandemics</term><term>Patient Selection</term><term>Risk Assessment</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32655019</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1735-8604</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Iranian journal of kidney diseases</Title><ISOAbbreviation>Iran J Kidney Dis</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.</ArticleTitle><Pagination><MedlinePgn>247-255</MedlinePgn></Pagination><Abstract><AbstractText>Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dashti-Khavidaki</LastName><ForeName>Simin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nephrology Rsearch Center, Tehran University of Medical Sciences, Tehran, Iran. dashtis@sina.tums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalili</LastName><ForeName>Hossein</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nourian</LastName><ForeName>Anahid</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Iran J Kidney Dis</MedlineTA><NlmUniqueID>101316967</NlmUniqueID><ISSNLinking>1735-8582</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32655019</ArticleId><ArticleId IdType="pii">5775/1183</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001167 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001167 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32655019
|texte= Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32655019" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |